Were the Eton (ETON) CEO’s share sales in a single trade or multiple trades?

The sales were executed in multiple trades at different prices between $31.59 and $32.55 per share. The Form 4 states that the reported prices are weighted averages and detailed trade information is available upon request.

Eton Pharmaceuticals (ETON) CEO reports open-market sale of 120,000 shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported open-market sales of a total of 120,000 shares of common stock on May 28, 2026. The transactions were executed at weighted-average prices, with individual trade prices ranging from $31.59 to $32.55 per share.

Following these sales, Brynjelsen directly held about 833,842 shares of Eton common stock. The filing notes that full details of the number of shares sold at each separate price are available upon request from the company, the SEC staff, or any security holder.

Insider Trade Summary

Net Seller: 120,000 shares ($3,825,717)

Net Sell 2 txns

Insider BRYNJELSEN SEAN

Role President & CEO

Sold 120,000 shs ($3.83M)

Type	Security	Shares	Price	Value
Sale	Common Stock	119,852	$31.88	$3.82M
Sale	Common Stock	148	$32.67	$5K

Holdings After Transaction: Common Stock — 833,842 shares (Direct, null)

Footnotes (1)

The shares were sold in multiple trades at prices ranging from $31.59 to $32.55. The price above reflects the weighted average sales price. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 120,000 shares Per-share price (block 1): $32.67 per share Per-share price (block 2): $31.88 per share +2 more

5 metrics

Shares sold 120,000 shares Total common shares sold on May 28, 2026

Per-share price (block 1) $32.67 per share One reported open-market sale price on May 28, 2026

Per-share price (block 2) $31.88 per share Second reported open-market sale price on May 28, 2026

Post-transaction holdings 833,842 shares CEO’s direct Eton common stock holdings after sales

Trade price range $31.59–$32.55 per share Range of prices for multiple trades on May 28, 2026

Key Terms

open-market sale, weighted average sales price, reporting person, Form 4

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"The price above reflects the weighted average sales price."

reporting person regulatory

"The Reporting Person will provide upon request"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 04:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRYNJELSEN SEAN

(Last)

(First)

(Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK

ILLINOIS

60010-7208

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2026		S		119,852	D	$31.88⁽¹⁾⁽²⁾	833,842	D
Common Stock	05/28/2026		S		148	D	$32.67	833,694	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $31.59 to $32.55. The price above reflects the weighted average sales price.

2. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Judith Matthews	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Eton Pharmaceuticals (ETON) CEO report in this Form 4?

The CEO of Eton Pharmaceuticals reported selling 120,000 shares of common stock in open-market transactions on May 28, 2026. These trades were executed at weighted-average prices within a disclosed price range.

How many Eton (ETON) shares did the CEO sell and at what prices?

The CEO sold a total of 120,000 Eton common shares in two open-market transactions. Trade prices ranged from $31.59 to $32.55 per share, with the reported per-transaction prices reflecting weighted-average sales prices.

How many Eton Pharmaceuticals (ETON) shares does the CEO hold after the sale?

After the reported transactions, the CEO directly holds approximately 833,842 shares of Eton common stock. This figure reflects his remaining direct ownership position as of the Form 4 reporting date following the May 28, 2026 sales.

Can Eton (ETON) investors obtain detailed pricing for each CEO trade on May 28, 2026?

Yes. The Form 4 notes the reporting person will provide full information on the number of shares sold at each separate price upon request by SEC staff, the issuer, or any security holder of Eton Pharmaceuticals.